| Therapeutic cancer vaccination with a peptide derived from the calreticulin exon 9 mutations induces strong cellular immune responses in patients with CALR-mutant chronic … J Handlos Grauslund, MO Holmström, NG Jørgensen, U Klausen, ... Frontiers in oncology 11, 637420, 2021 | 40 | 2021 |
| High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals MO Holmström, SM Ahmad, U Klausen, SK Bendtsen, E Martinenaite, ... Blood cancer journal 9 (2), 8, 2019 | 37 | 2019 |
| The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy SM Ahmad, E Martinenaite, M Holmström, MA Jørgensen, Ö Met, ... Oncoimmunology 7 (2), e1390641, 2018 | 36 | 2018 |
| Novel strategies for peptide-based vaccines in hematological malignancies U Klausen, S Holmberg, MO Holmström, NGD Jørgensen, JH Grauslund, ... Frontiers in immunology 9, 2264, 2018 | 27 | 2018 |
| Peptide vaccination against PD-L1 with IO103 a novel immune modulatory vaccine in multiple myeloma: A phase I first-in-Human trial NG Jørgensen, U Klausen, JH Grauslund, C Helleberg, TG Aagaard, ... Frontiers in Immunology 11, 595035, 2020 | 23 | 2020 |
| Cancer immune therapy for lymphoid malignancies: recent advances U Klausen, NGD Jørgensen, JH Grauslund, MO Holmström, MH Andersen Seminars in immunopathology 41, 111-124, 2019 | 20 | 2019 |
| An arginase1-and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial JH Grauslund, MO Holmström, E Martinenaite, TL Lisle, HJ Glöckner, ... Frontiers in Immunology 14, 1117466, 2023 | 5 | 2023 |
| Grønne Dahlager Jørgensen N, Grauslund JH, et al U Klausen An Immunogenic first-in-human immune Modulatory vaccine with PD-L1 and PD-L2 …, 2021 | 5 | 2021 |
| An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma U Klausen, N Grønne Dahlager Jørgensen, JH Grauslund, ... OncoImmunology 10 (1), 1975889, 2021 | 3 | 2021 |
| Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV U Klausen, JH Grauslund, NGD Jørgensen, SM Ahmad, M Jonassen, ... Frontiers in Oncology 12, 1023015, 2022 | 2 | 2022 |
| Therapeutic cancer vaccination for treatment of haematological cancers MO Holmström, JH Grauslund, NG Dahlager-Jørgensen, U Klausen, ... Ugeskrift for Laeger 181 (20A), V04190233-V04190233, 2019 | 1 | 2019 |
| Peptide vaccination in chronic lymphoproliferative malignancies: Targeting PDL1 and PDL2 in follicular lymphoma and chronic lymphocytic leukemia U Klausen University of Copenhagen, 2022 | | 2022 |
| PS1380 PEPTIDE VACCINATION AGAINST PD-L1 (IO103) IN MULTIPLE MYELOMA–A PHASE I FIRST IN HUMAN TRIAL NG Jørgensen, SM Ahmad, U Klausen, JH Grauslund, M Hansen, ... HemaSphere 3 (S1), 631-632, 2019 | | 2019 |
| Cancer immune therapy for the treatment of haematological malignancies MO Holmström, U Klausen, NG Jørgensen, S Holmberg, J Grauslund, ... Ugeskrift for Laeger 181 (10), V06180421-V06180421, 2019 | | 2019 |
| Cancerimmunterapi til behandling af hæmatologisk cancer KA T-CELLER Ugeskr Læger 181, V06180421, 2019 | | 2019 |
| Mikromiljøet som med-og modspiller i B-celle-non-Hodgkin-lymfomer U Klausen, MH Andersen, LM Pedersen Ugeskrift for læger 26 (2017; 179: V03170220), 2-6, 2017 | | 2017 |
| Micro-environment being agonist as well as antagonist in B-cell non-Hodgkin lymphoma pathology U Klausen, MH Andersen, LM Pedersen Ugeskr Læger, 2-6, 2017 | | 2017 |
